• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $HOOK

    HOOKIPA Pharma Inc.

    Subscribe to $HOOK
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

    IPO Year: 2019

    Exchange: NASDAQ

    Website: hookipapharma.com

    Peers

    $ACST
    $ASND
    $HUGE
    $HZNP
    $LUMO
    $MEIP
    $OYST

    Recent Analyst Ratings for HOOKIPA Pharma Inc.

    DatePrice TargetRatingAnalyst
    12/20/2024$48.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    11/15/2024$50.00 → $48.00Outperform
    RBC Capital Mkts
    12/2/2022Neutral → Underperform
    BofA Securities
    2/17/2022$15.00 → $8.00Buy
    HC Wainwright & Co.
    2/16/2022$3.00 → $4.00Outperform
    SVB Leerink
    11/12/2021$6.00Overweight → Equal-Weight
    Morgan Stanley
    11/11/2021$21.00 → $15.00Buy
    HC Wainwright & Co.
    11/10/2021$28.00 → $10.00Outperform
    SVB Leerink
    11/10/2021$24.00 → $17.00Outperform
    RBC Capital
    11/10/2021$25.00 → $11.00Market Outperform
    JMP Securities
    See more ratings

    HOOKIPA Pharma Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP and CFO Coelho Mary Theresa was granted 69,875 shares (SEC Form 4)

      4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

      7/24/24 4:18:15 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Peters Malte was granted 108,695 shares (SEC Form 4)

      4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

      7/24/24 4:17:16 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cassidy Sean A

      4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

      7/24/24 4:16:22 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Cassidy Sean A

      3 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

      7/24/24 4:15:17 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Peters Malte

      4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

      6/18/24 4:15:33 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kaufman David Ross

      4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

      6/18/24 4:15:32 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Van De Winkel Jan

      4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

      6/18/24 4:15:32 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Coelho Mary Theresa

      4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

      6/18/24 4:15:18 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director O'Neill Julie

      4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

      6/18/24 4:15:21 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Reilly Timothy P.

      4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

      6/18/24 4:15:15 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    HOOKIPA Pharma Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HOOKIPA Pharma downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded HOOKIPA Pharma from Outperform to Sector Perform and set a new price target of $2.00 from $48.00 previously

      12/20/24 7:37:05 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target

      RBC Capital Mkts reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $48.00 from $50.00 previously

      11/15/24 11:07:50 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma downgraded by BofA Securities

      BofA Securities downgraded HOOKIPA Pharma from Neutral to Underperform

      12/2/22 12:03:07 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on HOOKIPA Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of HOOKIPA Pharma with a rating of Buy and set a new price target of $8.00 from $15.00 previously

      2/17/22 10:31:27 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on HOOKIPA Pharma with a new price target

      SVB Leerink reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $4.00 from $3.00 previously

      2/16/22 5:01:55 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded HOOKIPA Pharma from Overweight to Equal-Weight and set a new price target of $6.00

      11/12/21 6:55:07 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on HOOKIPA Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of HOOKIPA Pharma with a rating of Buy and set a new price target of $15.00 from $21.00 previously

      11/11/21 6:23:24 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on HOOKIPA Pharma with a new price target

      SVB Leerink reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $10.00 from $28.00 previously

      11/10/21 12:34:42 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on HOOKIPA Pharma with a new price target

      RBC Capital reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $17.00 from $24.00 previously

      11/10/21 8:47:21 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on HOOKIPA Pharma with a new price target

      JMP Securities reiterated coverage of HOOKIPA Pharma with a rating of Market Outperform and set a new price target of $11.00 from $25.00 previously

      11/10/21 7:43:14 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    HOOKIPA Pharma Inc. SEC Filings

    See more
    • SEC Form DEFA14A filed by HOOKIPA Pharma Inc.

      DEFA14A - HOOKIPA Pharma Inc. (0001760542) (Filer)

      5/22/25 8:03:18 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)

      5/22/25 8:00:45 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by HOOKIPA Pharma Inc.

      10-Q - HOOKIPA Pharma Inc. (0001760542) (Filer)

      5/15/25 4:00:32 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by HOOKIPA Pharma Inc.

      10-K/A - HOOKIPA Pharma Inc. (0001760542) (Filer)

      4/30/25 5:03:22 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)

      2/20/25 4:01:17 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by HOOKIPA Pharma Inc.

      SCHEDULE 13D/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

      2/14/25 4:25:29 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by HOOKIPA Pharma Inc.

      SCHEDULE 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

      2/14/25 12:26:29 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)

      1/29/25 8:02:06 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by HOOKIPA Pharma Inc.

      DEFA14A - HOOKIPA Pharma Inc. (0001760542) (Filer)

      1/10/25 4:01:11 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)

      1/10/25 4:00:19 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    HOOKIPA Pharma Inc. Financials

    Live finance-specific insights

    See more

    HOOKIPA Pharma Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more

    HOOKIPA Pharma Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

      Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the CPS 20 or higher subgroup, comparing favorably to current standard of careCompany will host a conference call at 4:15 p.m. ET today NEW YORK and VIENNA, June 04, 2024 (GLOBE NEWSWIRE) -- H

      6/4/24 1:00:44 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

      Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizumab Two additional abstracts for HB-200 and HB-700 accepted for the ASCO 2024 Annual Meeting Company to host investor call at 8:00 a.m. ET on Thursday, April 25, 2024, to highlight path to potential registration; participant details below NEW YORK and VIENNA, Austria, April 25, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDA

      4/25/24 7:01:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

      NEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its third quarter 2023 financial results and business highlights on November 9, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight o

      11/2/23 4:01:00 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023

      NEW YORK and VIENNA, Austria, Aug. 03, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its second quarter 2023 financial results and business highlights on August 10, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight o

      8/3/23 7:01:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023

      NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its first quarter 2023 financial results and business highlights on May 11, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or pre

      5/4/23 7:01:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 15, 2023

      NEW YORK and VIENNA, March 08, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full year 2022 financial results before the market opens on Wednesday, March 15, 2023. The Company will host a live conference call and webcast at 8:30 AM ET to discuss its financial results and provide a corporate update. Conference Call & Webcast:    Date:  March 15, 2023Time:  8:30 AM ETUSA Dial In:  +1-800-715-9871UK Dial In:  0800-260-6466Austria Dial In:  +43 800-070-441Conference ID:  7669853Webcast:  Link The webcast and

      3/8/23 7:00:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma to Report Third Quarter 2022 Financial Results and Corporate Updates on November 14, 2022

      NEW YORK and VIENNA, Austria, Nov. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced it will release its third quarter 2022 financial results and Company update before the market opens on Monday, November 14, 2022. The company will not be conducting a conference call in conjunction with this earnings release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T ce

      11/7/22 7:00:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma to Report Second Quarter 2022 Financial Results on August 11, 2022

      NEW YORK and VIENNA, Austria, Aug. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it will release its second quarter 2022 financial results and Company update before the market open on Thursday, August 11, 2022. The Company will not be conducting a conference call in conjunction with this earnings release.About HOOKIPA HOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T c

      8/4/22 7:00:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022

      NEW YORK and VIENNA, Austria, May 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2022 financial results before the market open on Monday, May 16, 2022. The Company will not be conducting a conference call in conjunction with this earnings release.About HOOKIPA HOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, that are designed to mobilize and amplify targeted T cells and thereby fight or pr

      5/9/22 7:00:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Outlook

      Lead oncology candidate HB-200 demonstrated high antigen-specific T cell responses and encouraging anti-tumor activity in heavily pre-treated head and neck cancer patientsHOOKIPA received FDA Fast Track designation and advanced HB-200 to Phase 2 trial in combination with pembrolizumab, with data anticipated in H2 2022HOOKIPA and Gilead agreed to advance partnered HIV program, triggering $54 million commitment from GileadStrong 2021 year-end pro forma cash position of $156.9 million when giving effect to payments received in Q1 2022 from Gilead transaction and proceeds of $75 million public follow-on offering NEW YORK and VIENNA, Austria, March 24, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma I

      3/24/22 7:00:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV

      HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HIV) Under the collaboration agreement, HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial Primary completion expected H2 2025 NEW YORK and VIENNA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that enrollment is complete in th

      1/30/25 7:00:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

      NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious disease, today announced a notice to shareholders regarding U.K. disclosure requirements. HOOKIPA directs the attention of its shareholders to certain disclosure requirements applicable to the potential all-share acquisition by HOOKIPA of Poolbeg Pharma plc, which was announced on January 2, 2025. HOOKIPA's shares are admitted to trading on the NASDAQ Capital Market exchange. The relevant disclosure requirements are set out in

      1/7/25 4:05:00 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

      Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head and neck cancer Strength of HB-700 KRAS-inhibitor program highlighted by preclinical dataset presented at recent RAS Targeted Drug Development Summit NEW YORK and VIENNA, Austria, Nov. 14, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")

      11/14/24 4:05:00 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker

      NEW YORK and VIENNA, Nov. 11, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious disease, today announced that clinical collaborator Alan Ho, MD, PhD, Chief of the Head and Neck Oncology Service at Memorial Sloan Kettering Cancer Center, presented updated Phase 2 data from a study evaluating eseba-vec in combination with pembrolizumab as front line (1L) therapy in the setting of human papillomavirus type 16 positive (HPV16+) relapsed or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at the 39th Annual M

      11/11/24 4:05:00 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024

      NEW YORK and VIENNA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that updated Phase 2 data for eseba-vec (HB200) plus pembrolizumab in first-line recurrent/metastatic HPV16-positive head and neck cancer will be presented as a late-breaking poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), taking place in Houston, Texas from November 8-10, 2024. The poster will be presented by Alan Ho, MD, PhD, Chief of the Head and Neck

      10/31/24 9:17:13 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

      Study done in collaboration with Memorial Sloan Kettering and led by Dr. Winston Wong, Head and Neck Oncologist and Dr. Alan Ho, Chief of the Head and Neck Oncology Service IIT will evaluate eseba-vec in patients who are HPV16+ after treatment for curative intent Potential to expand the eseba-vec HNSCC opportunity into adjuvant care Initial safety and efficacy data from IIT expected in 2026 NEW YORK and VIENNA, Oct. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that r

      10/30/24 7:30:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

      NEW YORK and VIENNA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that the Company will present preclinical data related to the HB-700 program for the treatment of KRAS mutated cancers at the 6th Annual RAS-Targeted Drug Development Summit being held in Boston, Massachusetts from September 24-26, 2024. "HOOKIPA is very pleased to present a comprehensive preclinical proof-of-concept dataset related to HB-700, for the potential treatment of KRAS mutated cancers. KRAS mut

      9/24/24 7:30:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Announces Board of Directors Changes

      NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O'Neill as Non-Executive Chair of the Company's Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his o

      8/30/24 8:00:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

      NEW YORK and VIENNA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company"))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of the management team will participate in the H.C. Wainwright 26th Annual Global Investment Conference, taking place from September 9th-11th, 2024 in New York. Dr. Malte Peters, Hookipa's Chief Executive Officer, and Terry Coelho, Executive Vice President & Chief Financial Officer will be hosting one-on-one meetings with investors during the conference. In addition, Dr. Peters will participate in a Fireside Chat on Monday, September 9, 2024 at

      8/28/24 8:57:27 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

      New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 "AVALON-1" study with eseba-vec in Q4 2024 ASCO 2024 Presentation:   Reported best-in-class Phase 2 data for first-line HPV16+ head and neck cancer patients treated with eseba-vec (formerly HB-200) in combination with pembrolizumab during oral presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingRegulatory Progress:   Announced alignment with U.S. Food and Drug Administration (FDA) for the AVALON-1 Phase 2/3 pivotal trial design and protocol for eseba-vec, in combination with pembrolizumab for the first-li

      8/8/24 4:30:00 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

      SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

      11/14/24 6:07:08 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

      SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

      8/2/24 6:38:55 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by HOOKIPA Pharma Inc.

      SC 13G - HOOKIPA Pharma Inc. (0001760542) (Subject)

      7/8/24 6:51:26 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by HOOKIPA Pharma Inc.

      SC 13D - HOOKIPA Pharma Inc. (0001760542) (Subject)

      6/14/24 6:52:27 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by HOOKIPA Pharma Inc.

      SC 13G - HOOKIPA Pharma Inc. (0001760542) (Subject)

      5/31/24 5:25:48 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by HOOKIPA Pharma Inc. (Amendment)

      SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

      2/14/24 5:47:39 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by HOOKIPA Pharma Inc. (Amendment)

      SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

      2/14/24 4:26:22 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by HOOKIPA Pharma Inc. (Amendment)

      SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

      2/14/24 4:21:51 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by HOOKIPA Pharma Inc. (Amendment)

      SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

      12/22/23 4:18:56 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by HOOKIPA Pharma Inc. (Amendment)

      SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

      9/11/23 8:23:55 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    HOOKIPA Pharma Inc. Leadership Updates

    Live Leadership Updates

    See more
    • HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

      Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head and neck cancer Strength of HB-700 KRAS-inhibitor program highlighted by preclinical dataset presented at recent RAS Targeted Drug Development Summit NEW YORK and VIENNA, Austria, Nov. 14, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")

      11/14/24 4:05:00 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Announces Board of Directors Changes

      NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O'Neill as Non-Executive Chair of the Company's Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his o

      8/30/24 8:00:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

      New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 "AVALON-1" study with eseba-vec in Q4 2024 ASCO 2024 Presentation:   Reported best-in-class Phase 2 data for first-line HPV16+ head and neck cancer patients treated with eseba-vec (formerly HB-200) in combination with pembrolizumab during oral presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingRegulatory Progress:   Announced alignment with U.S. Food and Drug Administration (FDA) for the AVALON-1 Phase 2/3 pivotal trial design and protocol for eseba-vec, in combination with pembrolizumab for the first-li

      8/8/24 4:30:00 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

      Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr

      7/22/24 8:30:00 AM ET
      $ARVN
      $GMDA
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

      NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Mark Winderlich, PhD, as Chief Development Officer, effective April 1, 2024 (‘effective date'). Dr. Winderlich has rich experience leading multiple candidates through the drug development process to product approval in the United States and in Europe. "We are pleased to bring our search for a capable clinical development leader to such a swift, successful resolution and welcome Mark to the team," said Joern Aldag, Chief Executive Officer at HOOK

      1/16/24 7:01:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

      HOOKIPA on track to report Phase 2 data on HB-200 for head and neck cancer in combination with pembrolizumab in 2Q 2023Phase 1 clinical trials initiated for two programs (HB-300 for advanced prostate cancer and Gilead-partnered HB-400 for chronic hepatitis B)HB-700 for KRAS-mutated cancers achieved $10 million milestone payment in Roche collaboration NEW YORK and VIENNA, May 11, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the first quarter of 2023. "We are happy to report continued progress across ou

      5/11/23 7:01:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors

      NEW YORK and VIENNA, March 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that Terry Coelho will join its Board of Directors, Audit Committee and Compensation Committee, effective April 3, 2023. "Terry is an immensely valuable addition to our Board given her experience in business strategy, broad financial transactions and business development, and we are thrilled to welcome her to the team," said Joern Aldag, Chief Executive Officer at HOOKIPA. "Terry has worked with companies large and small and navigated fast-paced, complex business envi

      3/13/23 7:00:00 AM ET
      $FWBI
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors

      NEW YORK and VIENNA, Austria, Dec. 15, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today the promotion of Katia Schlienger, M.D., Ph.D., to Chief Medical Officer and the appointment of Malte Peters, M.D., to its Board of Directors, both effective January 1, 2023. "Katia has had a major impact on HOOKIPA's clinical development strategy and execution in immuno-oncology therapeutics and vaccines since she joined the Company in 2021. She will be leading the progression of our clinical programs to the next level, specifically our own programs in head and n

      12/15/22 7:00:00 AM ET
      $HOOK
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Appoints Tim Reilly, Ph.D. to its Board of Directors

      NEW YORK and VIENNA, Austria, April 20, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Tim Reilly, Ph.D. to its Board of Directors, effective immediately. "We're pleased to have Tim join our Board as we advance our oncology pipeline of novel arenaviral immunotherapeutics in and towards the clinic," said Joern Aldag, Chief Executive Officer at HOOKIPA. "Tim's experience in product development, especially driving early clinical development that supports eventual marketed products, is enormously relevant to our current focus. We wil

      4/20/22 7:00:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 Outlook

      Proprietary arenavirus immunotherapeutics platform demonstrated promising clinical activity with interim data from lead oncology and infectious disease candidatesFollow-on offering strengthened cash basis with $143 million available at year-end to support progression of Human Papillomavirus 16-positive (HPV16+) cancer and Cytomegalovirus (CMV) programs and pipeline expansion HOOKIPA on track to report additional clinical data on efficacy and T cell response in 2021 for HB-201 and HB-202 NEW YORK and VIENNA, Austria, March 18, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus p

      3/18/21 7:00:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care